This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2018 May;15(5):263.

doi: 10.1038/nrurol.2018.44. Epub 2018 Apr 5.

Prostate cancer: Quality of life during chemohormonal therapy

PMID: 29620061
DOI: 10.1038/nrurol.2018.44

Review

Prostate cancer: Quality of life during chemohormonal therapy

Clemens Thoma. Nat Rev Urol. 2018 May.

. 2018 May;15(5):263.

doi: 10.1038/nrurol.2018.44. Epub 2018 Apr 5.

Author

PMID: 29620061
DOI: 10.1038/nrurol.2018.44

No abstract available

PubMed Disclaimer

Similar articles

Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer.
Alibhai SM, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, Krahn M, Fleshner NE, Warde P, Canning SD, Klotz L, Naglie G. Alibhai SM, et al. J Clin Oncol. 2010 Dec 1;28(34):5038-45. doi: 10.1200/JCO.2010.29.8091. Epub 2010 Nov 1. J Clin Oncol. 2010. PMID: 21041715 Clinical Trial.
Androgen deprivation therapy for prostate cancer: not so simple.
Tadros NN, Garzotto M. Tadros NN, et al. Asian J Androl. 2011 Mar;13(2):187-8. doi: 10.1038/aja.2010.174. Epub 2011 Jan 31. Asian J Androl. 2011. PMID: 21278759 Free PMC article. No abstract available.
Prostate cancer: quality of life after radiation and androgen deprivation.
Makarov DV, Penson DF. Makarov DV, et al. Nat Rev Urol. 2009 Sep;6(9):477-8. doi: 10.1038/nrurol.2009.168. Nat Rev Urol. 2009. PMID: 19727147 No abstract available.
Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function.
Iversen P, Melezinek I, Schmidt A. Iversen P, et al. BJU Int. 2001 Jan;87(1):47-56. doi: 10.1046/j.1464-410x.2001.00988.x. BJU Int. 2001. PMID: 11121992 Review. No abstract available.
Choosing a prostate cancer drug.
Baker H. Baker H. Br J Nurs. 2014 Sep 11-24;23(16):S14, S16. doi: 10.12968/bjon.2014.23.Sup16.S14. Br J Nurs. 2014. PMID: 25203849 Review. No abstract available.

See all similar articles

Cited by

Identification of biomarkers of hepatocellular carcinoma gene prognosis based on the immune-related lncRNA signature of transcriptome data.
Ma A, Sun Y, Ogbodu RO, Xiao L, Deng H, Zhou H. Ma A, et al. Funct Integr Genomics. 2023 Mar 28;23(2):104. doi: 10.1007/s10142-023-01019-x. Funct Integr Genomics. 2023. Retraction in: Funct Integr Genomics. 2024 May 11;24(3):87. doi: 10.1007/s10142-024-01366-3. PMID: 36976410 Retracted.
A novel programmed cell death signature predicts clinical outcomes in clear cell renal cell carcinoma and identifies PLK1 as a therapeutic target.
Tan HT, Ma CY, Sun CH, Sun SZ, Zhang MX, Wang JF. Tan HT, et al. Apoptosis. 2025 Aug;30(7-8):1797-1825. doi: 10.1007/s10495-025-02126-9. Epub 2025 Jun 9. Apoptosis. 2025. PMID: 40488834
New insight on the correlation of immune landscapes with immune markers expression in different risk classification of gastrointestinal stromal tumors.
Zhang Q, Sun X, Hou Y, Gao X, Shen K, Qin X. Zhang Q, et al. J Gastroenterol. 2023 Jun;58(6):527-539. doi: 10.1007/s00535-023-01981-0. Epub 2023 Mar 24. J Gastroenterol. 2023. PMID: 36961557
Immunological role and prognostic value of ITGA3 and ITGA5 in oral squamous cell carcinoma.
Wang L, Xu X, Zeng D, Peng Q. Wang L, et al. Sci Rep. 2025 Aug 17;15(1):30046. doi: 10.1038/s41598-025-16026-0. Sci Rep. 2025. PMID: 40820179 Free PMC article.
Comprehensive pan-cancer analysis reveals SIRT5 is a predictive biomarker for prognosis and immunotherapy response.
Ji Y, Li C, Wan S, Zhang K, Liu Y, Shi S. Ji Y, et al. Funct Integr Genomics. 2024 Mar 19;24(2):60. doi: 10.1007/s10142-024-01338-7. Funct Integr Genomics. 2024. PMID: 38499806

References

1. J Clin Oncol. 2018 Apr 10;36(11):1088-1095 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information